COMMUNIQUÉS West-GlobeNewswire
-
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
16/07/2026 -
BienRaíz Launches 240 mg Magnesium Glycinate Supplement, Expanding Its Daily Wellness Portfolio with Targeted Mineral Support
16/07/2026 -
4TEEN4 Receives U.S. FDA Fast Track Designation for Invobenitug in Cardiogenic Shock
16/07/2026 -
Diagonal Therapeutics Announces First Patient Dosed in Phase 1/2 DIAMOND Clinical Trial of DIAG723 for Hereditary Hemorrhagic Telangiectasia (HHT)
16/07/2026 -
Arletta Pharma Solutions Receives FDA Response Supporting the Clinical Development Program of Lybrido™ for Female Sexual Interest/Arousal Disorder in the US
16/07/2026 -
Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year
16/07/2026 -
Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals
16/07/2026 -
Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development
16/07/2026 -
argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
16/07/2026 -
Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30
16/07/2026 -
Curaechoice and Symbol Health Solutions Partner to Transform Employer Healthcare with Integrated Onsite Care and Nationwide No-Cost Access
16/07/2026 -
Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026
15/07/2026 -
Celldex Announces Planned Transition of Chief Financial Officer
15/07/2026 -
Neutrolis Announces New England Journal of Medicine Publication Demonstrating First Clinical Evidence for NET-Degrading Therapy in Severe, Treatment-Refractory Systemic Lupus Erythematosus (SLE) Caused by DNASE1L3 Deficiency
15/07/2026 -
Rakovina Therapeutics Announces $1.5 Million Private Placement
15/07/2026 -
Artificial Organs Publishes Independent Commentary on Picard Medical and SynCardia's Emperor Total Artificial Heart Program
15/07/2026 -
PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026
15/07/2026 -
RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer
15/07/2026 -
Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026
15/07/2026
Pages